VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today announced that in a recent meeting the U.S. Food and Drug Administration (FDA) concurred with the Company’s approach to ...

Background: As the use of immune checkpoint inhibitors in postoperative adjuvant chemotherapy for patients with programmed death-ligand 1 (PD-L1)-expressing lung cancer has been increasing, it is ...

The DEPEND study demonstrates that checkpoint inhibitor nivolumab (Opdivo®) works best with high levels of PD-L1 biomarker, but does not work well with low levels of PD-L1 Multikine* is uniquely ...

Cancer immunotherapy has been a game-changer, but many tumors still find ways to slip past the immune system. New research ...

Genomic landscape study of esophago-gastric adenocarcinoma (EGAC) in young patients under the age of 30 years. Relationship between the number of biopsy specimens and PD-L1 positivity.

Role for immune checkpoint blockade in BRCA2-mutant prostate cancer. This is an ASCO Meeting Abstract from the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium. This abstract does not include a full ...

A new analysis of real-world data show that just as in solid tumors, higher tumor mutational burden (TMB) and PD-L1 expression in blood cancers are linked to less-optimistic prognoses. Their ...

Cancer immunotherapy has transformed modern oncology by harnessing the body's own immune system to combat malignant disease.

Treatment responses to Xalkori were not affected by PD-L1 expression in patients with advanced non-small cell lung cancer and ROS1 rearrangements. Patients with advanced non-small cell lung cancer ...